The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. (Q51955521)

18 April 2018

title

The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. (English)

1 reference

18 April 2018

author name string

Jun Liu

1

1 reference

18 April 2018

Nicholas Ngai

2

1 reference

18 April 2018

Geoffrey W Stone

3

1 reference

18 April 2018

Feng Yun Yue

4

1 reference

18 April 2018

Mario A Ostrowski

5

1 reference

18 April 2018

language of work or name

English

0 references

publication date

30 June 2009

1 reference

18 April 2018

published in

Vaccine

1 reference

18 April 2018

volume

27

1 reference

18 April 2018

issue

37

1 reference

18 April 2018

page(s)

5077-5084

1 reference

18 April 2018

HIV vaccine research: the way forward

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Progress and obstacles in the development of an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

7 January 2021

HIV/AIDS vaccines: 2007.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

TNF/TNFR family members in costimulation of T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

The costimulation-regulated duration of PKB activation controls T cell longevity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Costimulation of CD8 T cell responses by OX40.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

OX40 ligation of CD4+ T cells enhances virus-specific CD8+ T cell memory responses independently of IL-2 and CD4+ T regulatory cell inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

NYVAC: a highly attenuated strain of vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

HIV-1 prophylactic vaccine trials in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Safety profile of recombinant canarypox HIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Use of viral vectors for the development of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Unidirectional development of CD8+ central memory T cells into protective Listeria-specific effector memory T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Lineage relationship and protective immunity of memory CD8 T cell subsets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

IL-12 is required for anti-OX40-mediated CD4 T cell survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Differential requirements for OX40 signals on generation of effector and central memory CD4+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Regulation of CD4 T cell memory by OX40 (CD134).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

CD4(+)CD3(-) accessory cells costimulate primed CD4 T cells through OX40 and CD30 at sites where T cells collaborate with B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

IL-4-activated STAT-6 inhibits IFN-gamma-induced CD40 gene expression in macrophages/microglia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.046

10.1016/J.VACCINE.2009.06.046

7 January 2021

Identifiers

DOI

1 reference

18 April 2018

PubMed ID

19573639

1 reference

18 April 2018